PT Prodia Diagnostic Line Tbk
IIDX:PRDL136.00
IDR
+4.00
(+3.03%)
ISIN
ID1000214109
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Cristina Sandjaja
- Full Time Employees
- 81
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Cikarang Indonesia
- IPO Date
- Jul 9, 2026
- Website
- proline.co.id
- Similar Companies
- Business
- PT Prodia Diagnostic Line, operating commercially under the trade name Proline, is an Indonesia-based manufacturer and distributor of in vitro diagnostic (IVD) medical devices, clinical chemistry reagents, and healthcare laboratory testing solutions. Founded in 2010 as a specialized manufacturing subsidiary within the Prodia Group, the company is headquartered in Jakarta, Indonesia, with primary manufacturing, quality assurance, and warehousing operations situated in the Jababeka Industrial Estate in Cikarang, West Java. PT Prodia Diagnostic Line primarily focuses on the local formulation, filling, packaging, and commercialization of diagnostic reagents and related medical laboratory consumables for public and private healthcare providers across Indonesia and regional markets. The company's core product and service portfolio encompasses several specialized categories: Clinical Chemistry Reagents, comprising liquid-stable enzymatic, colorimetric, and immunoturbidimetric test reagents for monitoring lipid profiles, renal function, liver enzymes, diabetes biomarkers, cardiac markers, electrolytes, and metabolic substrates; Quality Control Materials and Calibrators, offering multi-analyte human serum controls, targeted calibrators, and reference materials designed for open and closed automated clinical chemistry analyzers; Rapid Diagnostic Tests and Point-of-Care Testing (POCT) Kits, delivering qualitative and semi-quantitative screening devices for infectious diseases, routine urinalysis, and rapid clinical screening; OEM and Contract Manufacturing Services, providing private-label reagent formulation, automated liquid bottling, blister packaging, and regulatory dossier preparation for domestic and international diagnostic equipment manufacturers; and Technical and Laboratory Support Services, providing analyzer application support, assay protocol adaptation, instrument maintenance, and quality assurance consultation. PT Prodia Diagnostic Line serves a broad customer base that includes government and private hospital networks, commercial clinical laboratories, primary health centers (Puskesmas), blood transfusion units, and medical supply distributors. In recent developments, PT Prodia Diagnostic Line has significantly expanded its operational scale and strategic market positioning in alignment with Indonesia's national health system transformation and domestic medical device self-sufficiency mandates. The company has achieved elevated Domestic Component Level (Tingkat Komponen Dalam Negeri or TKDN) certifications across an expanded line of clinical chemistry reagents, facilitating enhanced participation in national healthcare supply frameworks and public procurement via the government's electronic catalog (e-Katalog LKPP). Operationally, the company has completed infrastructure and cleanroom modernizations at its Cikarang production facility under Good Manufacturing Practice for Medical Devices (CPAKB) and ISO 13485 standards, substantially boosting automated filling capacity. In addition, PT Prodia Diagnostic Line has strengthened strategic technology transfer agreements and co-manufacturing partnerships with international in vitro diagnostic developers, including DiaSys Diagnostic Systems GmbH, while launching expanded assay panels for chronic metabolic disorders and broadening third-party contract manufacturing solutions for multinational healthcare brands operating in Southeast Asia.